Marginal ulcer continues to be a major source of morbidity over time following gastric bypass.
Anastomotic ulcer
Gastric bypass
Marginal ulcer
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
08
06
2018
accepted:
04
12
2018
pubmed:
14
12
2018
medline:
19
5
2020
entrez:
14
12
2018
Statut:
ppublish
Résumé
Marginal ulcerations (MU) are a common and concerning complication following Roux-en-Y gastric bypass (RYGB) surgery. The aim of the present study was to examine the progression of MU and identify risk factors for the need for surgical intervention in patients with MU following RYGB. A New York state longitudinal administrative database was queried to identify patients who underwent RYGB between 2005 and 2010 and who were followed for at least 4 years for the development of MU using ICD-9 and CPT codes. Patients with perforation as their first presentation of MU were excluded. Multivariable Cox proportional hazard model was built to identify risk factors for surgical intervention. Hazard ratios (HR) with 95% confidence intervals (CI) were reported. We identified 35,075 patients who underwent RYGB. Mean age was 42.47 ± 10.90 years and most were female (81.08%). There were 2201 (6.28%) patients with MU, of which 204 (9.27% of MU; 0.58% of RYGB overall) required surgery. The estimated cumulative incidence of having surgical intervention 1, 2, 5, and 8 years after MU diagnosis was 6% (95% CI 5-7%), 8% (95% CI 7-9%), 13% (95% CI 11-14%), and 17% (95% CI 13-20%), respectively. At time of MU diagnosis, younger age (HR 0.93 every 5 years, 95% CI 0.87-0.99), white race (HR 1.60, 95% CI 1.15-2.23), and weight loss (HR 2.82, 95% CI 1.62-4.88) were independent risk factors for subsequent surgical intervention for MU. Estimated cumulative incidence of MU recurrence was 15% (95% CI 9-22%) and 24% (95 CI% 15-32%) at 6 and 12 months after surgical intervention. The need for surgical intervention for MU after RYGB is uncommon. Young age, white race, and marked weight loss are risk factors for surgical intervention. Such patients may benefit from early intensive medical therapy at the time of MU diagnosis.
Sections du résumé
BACKGROUND
Marginal ulcerations (MU) are a common and concerning complication following Roux-en-Y gastric bypass (RYGB) surgery. The aim of the present study was to examine the progression of MU and identify risk factors for the need for surgical intervention in patients with MU following RYGB.
METHODS
A New York state longitudinal administrative database was queried to identify patients who underwent RYGB between 2005 and 2010 and who were followed for at least 4 years for the development of MU using ICD-9 and CPT codes. Patients with perforation as their first presentation of MU were excluded. Multivariable Cox proportional hazard model was built to identify risk factors for surgical intervention. Hazard ratios (HR) with 95% confidence intervals (CI) were reported.
RESULTS
We identified 35,075 patients who underwent RYGB. Mean age was 42.47 ± 10.90 years and most were female (81.08%). There were 2201 (6.28%) patients with MU, of which 204 (9.27% of MU; 0.58% of RYGB overall) required surgery. The estimated cumulative incidence of having surgical intervention 1, 2, 5, and 8 years after MU diagnosis was 6% (95% CI 5-7%), 8% (95% CI 7-9%), 13% (95% CI 11-14%), and 17% (95% CI 13-20%), respectively. At time of MU diagnosis, younger age (HR 0.93 every 5 years, 95% CI 0.87-0.99), white race (HR 1.60, 95% CI 1.15-2.23), and weight loss (HR 2.82, 95% CI 1.62-4.88) were independent risk factors for subsequent surgical intervention for MU. Estimated cumulative incidence of MU recurrence was 15% (95% CI 9-22%) and 24% (95 CI% 15-32%) at 6 and 12 months after surgical intervention.
CONCLUSIONS
The need for surgical intervention for MU after RYGB is uncommon. Young age, white race, and marked weight loss are risk factors for surgical intervention. Such patients may benefit from early intensive medical therapy at the time of MU diagnosis.
Identifiants
pubmed: 30543040
doi: 10.1007/s00464-018-06618-5
pii: 10.1007/s00464-018-06618-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3451-3456Références
Surg Obes Relat Dis. 2006 Jul-Aug;2(4):455-9
pubmed: 16925380
Surg Obes Relat Dis. 2009 May-Jun;5(3):317-22
pubmed: 19136312
Surg Obes Relat Dis. 2010 Sep-Oct;6(5):557-8
pubmed: 20870187
Obes Surg. 2011 Nov;21(11):1671-5
pubmed: 21739350
Surg Obes Relat Dis. 2011 Sep-Oct;7(5):656-8
pubmed: 21865096
N Engl J Med. 2012 Apr 26;366(17):1577-85
pubmed: 22449317
Surg Endosc. 2012 Oct;26(10):2789-96
pubmed: 22543994
Surg Endosc. 2013 Feb;27(2):384-9
pubmed: 22936436
Surg Obes Relat Dis. 2014 Mar-Apr;10(2):229-34
pubmed: 24462313
Obes Surg. 2015 May;25(5):805-11
pubmed: 25381115
Lancet. 2015 Sep 5;386(9997):964-73
pubmed: 26369473
Surg Obes Relat Dis. 2017 Apr;13(4):588-593
pubmed: 28215394
Surg Endosc. 2018 Mar;32(3):1215-1222
pubmed: 28842805
J Am Coll Surg. 1997 Jul;185(1):1-7
pubmed: 9208953
Obes Surg. 1998 Oct;8(5):505-16
pubmed: 9819081